Cellectricon, a services provider dedicated to advancing neuroscience drug discovery, has launched the Neuroinflammation Research Service module designed to expedite the development of treatments for neurodegenerative and neuropsychiatric disorders. The service has been refined and extensively tested over three years with several pharma and biopharma clients.   Evidence suggests that inflammatory responses in the CNS play a key role in the progression of a broad range of diseases, modulating b...